EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Stake Lowered by Oracle Investment Management Inc.

Oracle Investment Management Inc. decreased its position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 91.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,500 shares of the company's stock after selling 350,000 shares during the period. EyePoint Pharmaceuticals accounts for about 0.1% of Oracle Investment Management Inc.'s investment portfolio, making the stock its 15th largest holding. Oracle Investment Management Inc.'s holdings in EyePoint Pharmaceuticals were worth $242,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. RA Capital Management L.P. bought a new stake in shares of EyePoint Pharmaceuticals in the 4th quarter worth $23,705,000. One68 Global Capital LLC acquired a new position in EyePoint Pharmaceuticals during the fourth quarter worth about $192,000. Schonfeld Strategic Advisors LLC bought a new stake in EyePoint Pharmaceuticals in the fourth quarter worth about $91,000. TCG Crossover Management LLC lifted its holdings in EyePoint Pharmaceuticals by 287.3% in the 4th quarter. TCG Crossover Management LLC now owns 3,572,335 shares of the company's stock valued at $26,614,000 after acquiring an additional 2,650,000 shares during the last quarter. Finally, Nantahala Capital Management LLC bought a new position in shares of EyePoint Pharmaceuticals during the 4th quarter valued at about $4,470,000. 99.41% of the stock is currently owned by institutional investors and hedge funds.

EyePoint Pharmaceuticals Price Performance

EyePoint Pharmaceuticals stock traded up $0.17 during midday trading on Friday, reaching $7.30. The stock had a trading volume of 690,968 shares, compared to its average volume of 879,558. The firm's fifty day simple moving average is $6.00 and its two-hundred day simple moving average is $7.66. EyePoint Pharmaceuticals, Inc. has a twelve month low of $3.91 and a twelve month high of $14.00. The firm has a market cap of $502.32 million, a price-to-earnings ratio of -3.65 and a beta of 1.39.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last issued its quarterly earnings results on Wednesday, March 5th. The company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.10). The business had revenue of $11.60 million for the quarter, compared to analysts' expectations of $11.02 million. EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. As a group, sell-side analysts predict that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently commented on EYPT. StockNews.com upgraded shares of EyePoint Pharmaceuticals to a "sell" rating in a report on Friday, March 14th. Chardan Capital reaffirmed a "buy" rating and issued a $33.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. Citigroup initiated coverage on EyePoint Pharmaceuticals in a research note on Tuesday, January 7th. They set a "buy" rating and a $33.00 price objective for the company. Finally, HC Wainwright restated a "buy" rating and issued a $22.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. One investment analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat, EyePoint Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $26.63.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.